GBG
Government
Bioscience
Grants

Updated Monthly

June 9, 2022

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding

Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG
Government
Bioscience
Grants

Table of Contents

GBG Report

Updated Monthly

June 9, 2022

https://www.g2gconsulting.com/gbg-reporting-service/

June 17, 2022 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 10-10:30am EDT (FREE and open to all) then from 10:30-11am EDT (premium service and private consultation for G2G and GBG customers). Click here to register.

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE OFFICE OF SCIENTIFIC RESEARCH (2)		
1.	Air Force Office of Scientific Research Broad Agency Announcement (DoD/Air Force) FA9550-18-S-0003	This BAA's focus is on research areas that offer significant and comprehensive benefits to national warfighting and peacekeeping capabilities. Research topics in the Chemistry and Biological sciences categories include Biophysics; Human Performance and Biosystems; Mechanics of Multifunctional Materials and Microsystems; Molecular Dynamics and Theoretical Chemistry; Natural Materials, Systems, and Extremophiles; and Organic Materials Chemistry. https://www.grants.gov/web/grants/view-opportunity.html?oppId=305996	Dependent upon proposal	Proposals accepted on a rolling basis
2.	Research Interests of the Air Force Office of Scientific Research (DoD/Air Force) FA9550-21-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Engineering and Complex Systems team leads the discovery and development of the fundamental and integrated science that advances future air and space flight. The Information and Networks Team is organized to support many U.S. Air Force and Space Force priority areas including autonomy, space situational awareness, and cyber security. The Physical Sciences Team leads the discovery and transition of foundational physical science to enable air, space, and cyber power. The Chemistry and Biological Sciences Team is responsible for research activities in fundamental chemistry, biology, mechanics, and biophysics research. https://www.grants.gov/web/grants/view-opportunity.html?oppId=334084	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
		ALZHEIMER'S DISEASE (4)		
3.	Alzheimer's Drug-Development Program (U01 Clinical Trial Optional) (NIH/NIA) PAR-22-047	This FOA supports the Phase I development of novel small-molecule and biologic drug candidates that prevent AD, slow its progression, or treat its cognitive and behavioral symptoms. Participants will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics; Absorption, Distribution, Metabolism, Excretion, Toxicology; formulation development; chemical synthesis under GMP; IND-enabling studies; and initial Phase I clinical testing. https://grants.nih.gov/grants/guide/pa-files/PAR-22-047.html	Up to $1.5 million per year, for up to 5 years	Letter of intent: 9/5/22 Proposal: 10/5/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ALZHEIMER'S DISEASE		

4.	FY22 Peer Reviewed Alzheimer's Research Program
	Accelerating Diagnostics Research Award (ADRA)
	Investigator- Initiated Research Award (IIRA)
	Translational Research Award (TRA)
	(DoD/CDMRP)
	
	W81XWH-22-PRARP-ADRA
	W81XWH-22-PRARP-IIRA
	W81XWH-22-PRARP-TRA
		Applications submitted to the FY22 PRARP must address one or more of the following Focus Areas:
		• Individual, caregiver, and family support
		• Environmental, Diagnostic, and Prognostic Factors. Research of interest may include, but is not limited to:
		  • Identification and validation of biomarkers for diagnosis and prognosis of AD and ADRD.
		  • Risk and resiliency factors for development of AD/ADRD during and after military service, such as genetic, physiological, psychosocial, and life history.
		  • Epidemiological studies examining TBI and/or military service-related factors, including TBI and AD/ADRD development.
		• Fundamental research
		https://cdmrp.army.mil/funding/prarp
			Up to $2.5 million, for up to 4 years Dependent upon award mechanism\	Pre-Application: 6/17/22
				Proposal: 7/25/22

		AMYOTROPHIC LATERAL SCLEROSIS (1)		
5.	Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required) (NIH/NINDS/OD) RFA-NS-22-071	This FOA encourages grant applications for the conduct of scientific research utilizing data from expanded access (EA) for investigational drugs or biological products. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-071.html	Up to $8.25 million per year, for up to 4 years	Proposal: 6/17/22
		ARMY APPLICATIONS LAB (1)		
6.	Army Applications Lab BAA for Disruptive Applications (DoD/Army) W911NF-19-S-0004	AAL is interested in any and all technologies which can be shown to enable the Army of 2028 to be ready to deploy, fight, and win decisively against any adversary, anytime, and anywhere, in a joint, multi- domain, high-intensity conflict, while simultaneously deterring others and maintaining its ability to conduct irregular warfare. https://www.grants.gov/web/grants/view-opportunity.html?oppId=315517	Dependent upon proposal	Proposals accepted through 5/1/24 Pre-proposal is required
		ARMY RESEARCH LABORATORY (1)		
7.	Army Research Laboratory Broad Agency Announcement for Basic and Applied Scientific Research (DoD/Army) W911NF-17-S-0003-11	The ARL BAA seeks proposals for research based on the following S&T campaigns: Computational Sciences, Materials Research, Sciences for Maneuver, Information Sciences, Sciences for Lethality and Protection, Human Sciences, and Assessment and Analysis. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppId=292896	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY RESEARCH OFFICE (2)		
8.	Army Research Office Broad Agency Announcement for Fundamental Research (DoD/Army) W911NF-17-S-0002-07	ARL's strategy is based on eleven Foundational Research Competencies: Biological and Biotechnology Sciences; Electromagnetic Spectrum Sciences; Energy Sciences; Humans in Complex Systems; Mechanical Sciences; Military Information Sciences; Network, Cyber and Computational Sciences; Photonics, Electronics, and Quantum Sciences; Sciences of Extreme Materials; Terminal Effects; and Weapons Sciences. These competencies are structured to create discovery, innovation, and transition of technologies for Army transformational overmatch. https://www.grants.gov/web/grants/view-opportunity.html?oppId=292877	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
9.	Army Research Office Broad Agency Announcement Staff Research Program (DoD/Army) W911NF20S0003	The purpose of the program is to enable ARO scientific staff to maintain and expand professional competence in support of fulfilling the ARO mission through the conduct of hands-on, basic research. Research efforts will involve scientific study directed toward advancing the state-of-the-art or increasing knowledge and scientific understanding in engineering, physical, life and information sciences. https://www.arl.army.mil/wp-content/uploads/2020/04/arl-baa-Staff-Research-PA.pdf	Dependent upon proposal	Proposals accepted on a rolling basis until 2/19/25
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (2)		
10.	Dear Colleague Letter: Stimulating Integrative Research in Computational Cognition (CompCog)(DREAM Sentinels) (NSF) NSF 22-091	The NSF is interested in receiving proposals to existing programs, listed here, that explore computational models of human cognition, perception, and communication and that integrate considerations and findings across disciplines. https://beta.nsf.gov/funding/opportunities/stimulating-integrative-research-computational-cognition-compcog-0	Dependent upon proposal and award mechanism	Dependent upon program
11.	Dynamics, Control and Systems Diagnostics (NSF) PD-22-7569	The DCSD program promotes the fundamental science and engineering of dynamic systems to advance solutions to urgent societal problems, such as mitigating the impacts of climate change; responding to epidemics, cyber-attacks, extreme weather, and other natural and man-made events; promoting efficient and equitable production and distribution of resources; developing resilient infrastructure; improving the experience of work and learning; and meeting the challenges of aging and illness. https://beta.nsf.gov/funding/opportunities/dynamics-control-and-systems-diagnostics-dcsd-0	Dependent upon proposal	Proposals accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
12.	BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement (EZ-BAA) (HHS/BARDA) BAA-20-100-SOL-00002	BARDA is currently accepting submissions through the EZ-BAA for several AOIs: AOI #2: Infection Severity and Solving Sepsis; AOI #5: ReDirect (Repurposing Drugs in Response to Chemical Threats); AOI #8: Bringing Laboratory Testing to the Home.; AOI #9: Digital Health Tools for Pandemic Preparedness.; AOI #10: Next Generation Sequencing based Agnostic Diagnostic for Respiratory RNA Virus Pathogens; AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2; AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection; AOI #12: Mitigating Long-term Effects of Respiratory Distress; AOI #13: Endotyping for Host-Directed Therapeutics https://sam.gov/opp/0f026c861ae84ef499be99d7604ef3db/view https://drive.hhs.gov/partner.html	Up to $750,000, per award	Proposals accepted on a rolling basis until 2/3/23
13.	BARDA Broad Agency Announcement (HHS/BARDA) BARDABAA	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antibacterials; Radiological, Nuclear & Chemical Threat MCMs; Burn Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics. https://sam.gov/opp/550c21c541ac4c5ea14a52997a84a65d/view https://www.medicalcountermeasures.gov/barda/barda-baa	Dependent upon proposal	White Papers: 12/15/22
		BIODEFENSE (1)		
14.	Dear Colleague Letter: Sentinel Systems that Detect, Recognize, Actuate, and Mitigate Emergent Biological Threats (DREAM Sentinels) (NSF) NSF 22-077	Proposals should include biosensing and bioactuation elements that address a biological threat. The biosensing element should leverage the power of modern biotechnology and deliver robust and specific recognition of the biological threat. The results of bioactuation should alert the user, destroy the threat, protect the host, or initiate an immune response or other strategies that would mitigate the threat. https://beta.nsf.gov/funding/opportunities/sentinel-systems-detect-recognize-actuate-and-mitigate-emergent-biological	Dependent upon proposal and award mechanism	Proposals accepted on a rolling basis
		BIOMATERIALS (3)		
15.	Pre-Announcement: Data-Driven Tools to Accelerate the Clinical Translation of Novel Dental, Oral, and Craniofacial Biomaterials (R61/R33/R42/R44) (NIH/NIDCR) NOT-DE-22-009 (R61/R33) NOT-DE-22-010 (R42) NOT-DE-22-011 (R44)	These Notices encourage investigators with expertise and insights into ways to accelerate the clinical translation of novel biomaterials for dental, oral, and craniofacial (DOC) applications through development and implementation of advanced data-driven tools designed to overcome critical bottlenecks in R&D cycles that lead to delays in regulatory evaluations and translation to human use to begin to consider applying for this new FOA. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-009.html (R61/R33) https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-010.html (R42) https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-011.html (R44)	Up to $200,000 per year (Phase I) Up to $750,000 per year (Phase II)	Estimated post date: 7/11/22 Estimated proposal date: 11/10/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL PRODUCT DEVELOPMENT (1)		
16.	2022 Medical Innovation Challenge (TechConnect)	Pitch and connect your technology with leading corporate, investment and federal prospectors. Categories are: Devices & Sensors; Digital & Hardware; Therapeutics & Treatments; Materials & Manufacturing; and Readiness & Response. https://events.techconnect.org/DTCFall/medical_innovation_challenge/	Up to $35,000	Proposal: 6/30/22
		BONE MARROW FAILURE (2)		
17.	FY22 Bone Marrow Failure Idea Development Award (IDA) Investigator-Initiated Research Award (IIRA) (DoD/CDMRP) W81XWH-22-BMFRP-IDA W81XWH-22-BMFRP-IIRA	Applications submitted to the FY22 BMFRP must address one or more of the following focus areas: • Understand the causes and progression of BMF diseases • Find effective BMF treatments and cures https://cdmrp.army.mil/funding/bmfrp	Up to $800,000, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/29/22 Invited application: 9/23/22
		CANCER (73)		
18.	NOSI: Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments (NIH/NCI/ODP) NOT-CA-22-038	NCI is interested in proposed studies to adapt and scale-up the implementation of these interventions in accessible, affordable, and equitable ways in order to improve the prevention and early diagnosis of cancer in real-life settings. Interventions should meet conditions and requirements of the local health and social system context and address any other contextual factors identified as possible barriers. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-038.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/24
19.	NOSI: Understanding the Basic Mechanisms of Immune-related Adverse Events (irAEs) in Cancer Immunotherapy (NIH) NOT-CA-22-063	This NOSI, with 15 linked grants, aims to promote mechanistic research aimed at better understanding the pathophysiology of irAEs. It is anticipated that the mechanistic research supported through this NOSI will build the foundational knowledge which will ultimately lead to better strategies to predict, prevent and/or ameliorate toxicities that can arise as a consequence of current immunotherapeutic regimens, and improve treatment outcomes. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-063.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 7/5/24
20.	NOSI: Technologies and Informatics Tools for Cancer Metabolomics (NIH/NCI) NOT-CA-22-083	This announcement seeks to address the need for new technologies designed explicitly to overcome technical challenges and advance cancer metabolomics. Research could include launching new and innovative analytical and software platforms, improving the ability of researchers to process more complex samples, and/or developing novel computational approaches or tools that facilitate metabolomics data analysis, interpretation, and integration. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-083.html	Dependent upon proposal and award mechanism5/6/2022	Multiple deadlines; NOSI open through 12/31/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
21.	NOSI: Basic Mechanisms of Cannabis and Cannabinoid Action in Cancer (NIH/NCI) NOT-CA-22-085	This NOSI, with 16 linked grants, aims to promote research in understanding the mechanisms by which cannabis and cannabinoids affect cancer biology, cancer interception, cancer treatment and resistance, and management of cancer symptoms. https://grants.nih.gov/grants/guide/notice-files/NOT-CA-22-085.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/27
22.	Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-161	This FOA will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations with substantial community engagement. https://grants.nih.gov/grants/guide/pa-files/PAR-22-161.html	Dependent upon proposal, for up to 5 years	Letter of intent: optional Proposal: 7/29/22
23.	Research Opportunities in Established Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed) (NIH/NCI) PAR-22-162	NCI encourages grant applications to support research in established cancer epidemiology cohort studies. Applications must include hypothesis-based research using data from an established cohort study and are expected to include support for cohort maintenance, continued follow-up, and sharing of the existing resources in addition to addressing research questions across the cancer control continuum. https://grants.nih.gov/grants/guide/pa-files/PAR-22-162.html	Dependent upon proposal, for up to 5 years	Proposal: 7/29/22
24.	Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) (NIH/NCI) RFA-CA-22-027	This FOA will support studies that aim to better understand and/or address survivorship needs for individuals living with likely incurable cancer. Specifically, this RFA is intended to solicit applications proposing 1) observational studies to understand the trajectory of physical and psychological symptoms, patterns of care, and unmet needs; and/or 2) the development and testing of interventions to improve the delivery of comprehensive survivorship care in this group of cancer survivors. https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-027.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 8/30/22 Proposal: 9/30/22
25.	Pre-Announcement: FY22 Breast Cancer Research Program (BCRP) (DoD/CDMRP)	CDMRP is issuing a second round of awards: This pre-announcement anticipates The Breakthrough Award, Era of Hope Scholar Award, and Innovator Award. Applications submitted to the FY22 BCRP must address one or more of the overarching challenges listed here. https://cdmrp.army.mil/pubs/press/2022/22bcrppreann2	Up to $10 million, for up to 4 years Dependent upon award mechanism	TBD

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
26.	FY22 Breast Cancer, Transformative Breast Cancer Consortium Award (DoD/CDMRP) W81XWH-22-BCRP-TBCCA-2	The Transformative Breast Cancer Consortium Award is designed to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. https://cdmrp.army.mil/funding/bcrp	Up to $25 million, for up to 4 years	Pre-Application: 8/3/22 Invited proposal: 11/3/22
27.	FY22 Kidney Cancer Concept Award (CA) Postdoctoral and Clinical Fellowship Award (PCFA) (DoD/CDMRP) W81XWH-22-KCRP-CA W81XWH-22-KCRP-PCFA	Applications submitted to the FY22 KCRP must address one or more of the Focus Areas appropriate to each award. The Focus Areas include: • Conduct basic biology research on kidney cancer. • Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death. • Identify and develop new strategies for screening, early-stage detection, accurate diagnosis and prognosis prediction of kidney cancers. • Develop novel therapeutic strategies for the treatment of kidney cancer. https://cdmrp.army.mil/funding/kcrp	Up to $195,000 for up to 3 years Dependent upon award mechanism	Pre-Application: 6/23/22 Proposal: 7/14/22
28.	FY22 Lung Cancer, Clinical Translational Research Partnership Award (DoD/CDMRP) W81XWH-22-LCRP-CTRPA	This mechanism is intended to support a pilot, proof-of-principle, or early-phase clinical trial and associated correlative science. It is expected that the proposed trial will have a well-developed rationale, strong preliminary data, trial methodology, and execution plan. Any proposed preclinical studies in addition to the trial should be appropriately justified as to its necessity to inform and interpret trial results and the correlative science. https://cdmrp.army.mil/funding/pa/W81XWH-22-LCRP-CTRPA-GG.pdf	Up to $1.2 million, for up to 3 years	Letter of intent: 7/13/22 Proposal: 7/27/22
29.	FY22 Melanoma Research Program (MRP) Focused Program Award (FPA) Idea Award (IA) Melanoma Academy Scholar Award (MASA) Mid-Career Accelerator (MCAA) Team Science Award (TSA) (DoD/CDMRP) W81XWH-22-MRP-FPA W81XWH-22-MRP-IA W81XWH-22-MRP-MASA W81XWH-22-MRP-MCAA W81XWH-22-MRP-TSA	Applications submitted to the FY22 MRP must address one or more of the Focus Areas, which include: • Investigate topics relevant to rare melanomas that cover the entire research spectrum, from risk factors and initiation to distant macro-metastases, in model organisms and/or patients. • Identify and understand risk factor determinants for melanoma. • Develop prediction and surveillance tools for distinguishing patient populations at risk for a second primary diagnosis, recurrence, and/or metastasis. • Identify how the tumor microenvironment impacts tumor initiation, response to therapy, progression, recurrence, and/or dormancy. • Delineate the molecular pathways that influence metastatic spread, recurrence, and/or dormancy. https://cdmrp.army.mil/funding/mrp	Up to $2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 7/8/22 Invited Application: 10/5/22 (IA) Pre-Application: 9/14/22 Application: 10/5/22 (FPA/MASA/ MCAA/TSA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
30.	FY22 Ovarian Cancer Clinical Trial Award (DoD/CDMRP) W81XWH-22-OCRP-CTA	The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. https://cdmrp.army.mil/funding/pa/W81XWH-22-OCRP-CTA_GG.pdf	Up to $1.5 million, for up to 4 years	Pre-application: 6/22/22 Invited application: 8/5/22
31.	FY22 Pancreatic Cancer Idea Development Award (IDA) Translational Research Partnership Award (TRPA) (DoD/CDMRP) W81XWH-22-PCARP-IDA W81XWH-22-PCARP-TRPA	Applications submitted to the FY22 PCARP must address one or more of the following Focus Areas: • Early detection research for pancreatic cancer • Supportive care interventions, patient-reported outcomes, quality of life, and perspectives during treatment and survivorship • Understanding the relationship between metabolic disruptions in pancreatic cancer and their systemic effects, including diabetes and cachexia • Understanding precursors, origins, and early progression of pancreatic cancer • Understanding the events that promote pancreatic cancer metastasis • Understanding the relationship between oncogenic signaling and the tumor microenvironment that drives drug resistance and therapeutic response • New drug development targeted toward cancer sensitivity and resistance mechanisms including immune mechanisms of resistance https://cdmrp.army.mil/funding/pcarp	Up to $750,000, for up to 3 years Dependent upon award mechanism	Pre-Application: 7/8/22 Invited Application: 10/6/22
32.	FY22 Prostate Cancer Data Science Award (DSA) Early Investigator Research Award (EIRA) Health Disparity Research Award (HRDA) Idea Development Award (IDA) Physician Research Award (PRA) Translational Science (TSA) (DoD/CDMRP) W81XWH-22-PCRP-DSA W81XWH-22-PCRP-EIRA W81XWH-22-PCRP-HDRA W81XWH-22-PCRP-IDA W81XWH-22-PCRP-PRA W81XWH-22-PCRP-TSA	There are 6 awards included in the FY22 Prostate Cancer Research Program. Applications to the FY22 PCRP are required to address one or more of the following FY22 PCRP Overarching Challenges: • Improve quality of life to enhance outcomes and overall health and wellness for those impacted by prostate cancer • Develop treatments that improve outcomes for men with lethal prostate cancer • Advance health equity and reduce disparities in prostate cancer • Define the biology of prostate cancer progression to lethal prostate cancer to reduce death https://cdmrp.army.mil/funding/pcrp	Up to $1 million, for up to 3 years Dependent upon award mechanism	Pre-application: 7/7/22 Proposal: 7/28/22 (EIRA/PRA/IDA) Pre-application: 8/4/22 Proposal: 8/25/22 (DSA/HDRA/TSA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
33.	FY22 Peer Reviewed Cancer Program Behavioral Health Science Award (BHSA) Career Development Award (CDA) Convergent Science Cancer Consortium Development Award (CDCCDA) Translational Team Science Award (TTSA) (DoD/CDMRP) W81XWH-22-PRCRP-BHSA W81XWH-22-PRCRP-CDA W81XWH-22-PRCRP-CSCCDA W81XWH-22-PRCRP-TTSA	The FY22 PRCRP appropriation provides funds for research into cancers not addressed in the other CDMRP cancer programs. Applications must address at least one of the FY22 PRCRP Topic Areas, at least one of the Military Health Focus Areas listed below, and at least one of the PRCRP Overarching Challenges. Military Health Focus Areas: • Environmental/exposure risk factors associated with cancer • Gaps in cancer research that may affect mission readiness: • Gaps in cancer prevention, early detection/diagnosis, prognosis, and/or treatment that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries. • Gaps in quality of life and/or survivorship that may affect the general population but have a particularly profound impact on the health and well-being of military Service Members, Veterans, and their beneficiaries. https://cdmrp.army.mil/funding/prcrp	Up to $2.5 million, for up to 4 years Dependent upon award mechanism	Pre-application: 7/12/22 Proposal: 8/2/22 (BHSA/CDA/ TTSA) Pre-application: 8/17/22 Invited application: 9/7/22 (CSCCDA)
34.	FY22 Rare Cancers Concept Award (CA) Idea Development Award (IDA) Resource and Community Development Award (RCDA) (DoD/CDMRP) W81XWH-22-RCRP-CA W81XWH-22-RCRP-IDA W81XWH-22-RCRP-RCDA	CA and IDA applications submitted to the FY22 RCRP must address one or more of the following Focus Areas: • Biology and Etiology: Identify disease-defining molecular pathways, cell context, and microenvironment. • Research Model: Develop and validate rare tumor-specific models that can support clinical trial readiness. • Therapy: Identify novel therapeutic strategies, including drug repurposing. • RCDA applications submitted to the FY22 RCRP must address Platform Development. https://cdmrp.army.mil/funding/rcrp	Up to $600,000, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/22/22 Proposal: 9/30/22 (IDA/RCDA) Pre-Application: 7/18/22 Proposal: 8/29/22 (CA)
		CARDIOVASCULAR AND PULMONARY HEALTH (6)		
35.	NOSI: Diagnostics and Disease Management Tools for Use in Underserved Populations (NIH/NHLBI) NOT-HL-22-024	This NOSI aims to stimulate research focused on the development of transformative diagnostics and disease management tools for heart, lung, blood, or sleep (HLBS) disorders that are designed to meet the needs of the underserved populations. https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-024.html	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOSI open through 7/6/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CARDIOVASCULAR AND PULMONARY HEALTH		
36.	Catalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed) (NIH/NHLBI) RFA-HL-23-010	This Catalyze FOA solicits grant applications to rigorously validate transformative, multi-use platforms or technologies that can enable the next generation of predictive, diagnostic and therapeutic products or model systems relevant to heart, lung, blood and/or sleep (HLBS)-related diseases or disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-010.html	Up to $300,000 per year, for up to 2 years	Letter of intent: 6/21/22 Proposal: 7/21/22
37.	Catalyze: Product Definition for Small Molecules and Biologics (R61/R33 – CT Not Allowed) (NIH/NHLBI) RFA-HL-23-011 RFA-HL-23-012	The Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop potential therapeutic candidates a lead compound series to identify potential therapeutics to treat HLBS diseases and disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-011.html https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-012.html	Up to $350,000 per year, for up to 3 years Cost matching of at least 0.25:1 required for R33 grants	Letter of intent: 6/21/22 Proposal: 7/21/22
38.	Catalyze: Product Definition – Device Prototype Diagnostic Disease Target Identification and Assay Development, and Research Tool Development (R61/R33 – CT Not Allowed) (NIH/NHLBI) RFA-HL-23-013 RFA-HL-23-014	The Catalyze Product Definition initiative will provide the early stage translational support needed for the activities required to develop and test/modify device prototypes, identify diagnostic disease targets and develop associated assays, and develop research tools to treat HLBS diseases and disorders. https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-013.html https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-23-014.html	Up to $250,000 per year, for up to 3 years Cost matching of at least 0.25:1 required for R33 grants	Letter of intent: 6/21/22 Proposal: 7/21/22
		CHRONIC PAIN MANAGEMENT (3)		
39.	FY22 Chronic Pain Management Clinical Exploration Award (CEA) Investigator-Initiated Research Award (IIRA) Translational Research Award (TRA) (DoD/CDMRP) W81XWH-22-CPMRP-CEA W81XWH-22-CPMRP-IIRA W81XWH-22-CPMRP-TRA	Applications submitted to the FY22 CPMRP must address one or more of the following focus areas, appropriate to each award: Chronification of pain; Effectiveness or observational studies of novel treatments or untested techniques/approaches/pathways to chronic pain management; Development of non-opioid therapies and methods for the treatment of chronic pain; Comparative effectiveness studies; Implementation science; and Observational studies related to chronic pain. https://cdmrp.army.mil/funding/cpmrp	Up to $1.4 million, for up to 4 years Dependent upon award mechanism	Pre-application: 7/12/22 Invited proposal: 10/13/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLIMATE CHANGE (42)		
40.	NOSI: Climate Change and Health (NIH) NOT-ES-22-006	The goals of this 38-grant NOSI are: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, Tribal Nations, and nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally. https://grants.nih.gov/grants/guide/notice-files/NOT-ES-22-006.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
41.	NOSI: Innovative Technologies for Research on Climate Change and Human Health (R43/R44 SBIR (R43/R44 CT Optional) (NIH) NOT-ES-22-009 (R41/R42) NOT-ES-22-010 (R43/R44)	These NOSIs encourage grant applications from SBCs to develop commercializable tools, resources, and approaches to capture the effects of climate change and the associated impacts of extreme weather events on human health and to support adaptation or mitigation strategies to minimize health hazards and impacts from climate change. https://grants.nih.gov/grants/guide/notice-files/NOT-ES-22-009.html (R41/R42) https://grants.nih.gov/grants/guide/notice-files/NOT-ES-22-010.html (R43/R44)	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 4/5/23
		COGNITIVE AND BRAIN HEALTH (14)		
42.	Cornerstone (DoD/DARPA) HR001122S0022	The Cornerstone program will develop safe and effective Integrated Countermeasures to prevent brain injury. Military personnel face a high risk of TBI resulting in a debilitating long-term burden both to the person, as well as the healthcare infrastructure. Cornerstone will consist of two technical areas; (TA1) Identify, optimize, and validate prophylactic countermeasures that prevent relevant targets at sites of injury from initiating injury response(s) to kinetic injury; (TA2) Develop clinically relevant spatial and temporal delivery of countermeasures. https://sam.gov/opp/cab580ada8974119a6908fca0e986cd9/view	Dependent upon proposal	Abstract: 6/30/22 Proposal: 8/18/22
43.	NOSI: Innovative Technologies to Improve Assessments, Interventions, and Outcomes for Individuals with Intellectual and Developmental Disabilities (R43/R44) (NIH/NICHD) NOT-HD-22-009	This notice invites small business applications specifically aimed at developing or building upon existing technological tools to improve assessments, interventions, and outcomes for children and individuals with intellectual, developmental and physical disabilities. Applications proposing tools and/or technologies may include: home monitors, point-of-care diagnostic technologies, mobile devices, mobile device apps, and wearable sensors and monitors. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-009.html	Up to $275,766, for up to 2 years (Phase I) Up to $1.8 million, for up to 3 years (Phase II)	Proposal: 9/5/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
44.	Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed) (NIH/NINDS/NCATS) PAR-22-184	This FOA invites researchers to submit applications for support of clinical studies that address critical needs for clinical trial readiness in rare neurological and neuromuscular diseases. These studies should result in clinically validated biomarkers and clinical outcome assessment measures appropriate for use in upcoming clinical trials. https://grants.nih.gov/grants/guide/pa-files/PAR-22-184.html	Up to $750,000 per year, for up to 5 years	Letter of intent: 7/18/22 Proposal: 8/18/22
45.	Cognitive Neuroscience (CogNeuro) (NSF) PD 15-1699	The Cognitive Neuroscience Program seeks highly innovative proposals aimed at advancing a rigorous understanding of the neural mechanisms of human cognition. Central research topics for consideration by the program include attention, learning, memory, decision-making, language, social cognition, and emotions. https://beta.nsf.gov/funding/opportunities/cognitive-neuroscience-cogneuro	Dependent upon proposal, for up to 5 years	Proposal: 8/13/22
46.	NINDS Interdisciplinary Team Science Grant (RM1 Clinical Trial Optional) (NIH/NINDS) RFA-NS-22-036	This FOA is designed to support integrated efforts of three or more (up to six) PDs/PIs to pursue bold, impactful, and challenging research in any area within the scope of the NINDS mission. The research approach should be interdisciplinary in nature, and the research teams are expected to establish a common goal that requires collaboration, synergy, and managed team interactions. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-036.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/7/22 Proposal: 10/7/22
47.	BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 CT/Studies vary) (NIH) RFA-NS-22-039 RFA-NS-22-040	Applications should focus on overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-039.html https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-040.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/16/22 Proposal: 9/16/22
48.	BRAIN Initiative: Research Opportunities Using Invasive Neural Recording and Stimulating Technologies in the Human Brain (U01 Basic Experimental Studies with Humans Required) (NIH) RFA-NS-22-041	This RFA seeks applications to assemble diverse, integrated, multi-disciplinary teams that cross boundaries of interdisciplinary collaboration to overcome these fundamental barriers and to investigate high-impact questions in human neuroscience. Projects should maximize opportunities to conduct innovative in vivo neuroscience research made available by direct access to the brain from invasive surgical procedures. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-041.html	Dependent upon proposal, for up to 5 years	Letter of intent: 8/23/22 Proposal: 9/23/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COGNITIVE AND BRAIN HEALTH		
49.	Treatments for Lewy Body Dementias and Frontotemporal Dementias--Exploratory Clinical Trial (U01 Clinical Trial Required) (NIH/NIA/NINDS) RFA-NS-22-056	This FOA invites applications from investigators seeking to conduct exploratory clinical trials designed to test new treatments for patients with Lewy Body Dementia (LBD) or Frontotemporal Dementia (FTD). Applicants may propose to conduct either Phase I or Phase II clinical trials depending on the developmental stage of the potential therapeutic, but all trials must include patients with either LBD or FTD. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-056.html	Dependent upon proposal, for up to 5 years	Proposal: 11/21/22
50.	Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies For Acute Cerebroprotection- Interventions (U01/U44 Clinical Trial Not Allowed) (NIH/NINDS) RFA-NS-22-066 (U01) RFA-NS-22-067 (U44)	SPAN will facilitate the testing of up to 8 promising cerebroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke. Applicants must propose a research project involving a promising cerebroprotective intervention, supported by rigorous and extensive preliminary data, to be tested in SPAN. If successful, this network will accelerate the identification of the most promising cerebroprotective therapies for future pivotal clinical trials and span the gap between small businesses, preclinical testing laboratories, and a pipeline to clinical testing, in a cost-and time-effective fashion. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-066.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-067.html (U44)	Up to $225,000 per year, for up to 3 years (U01) Up to $300,000 per year, for up to 3 years (U44) Recipients are expected to contribute to the Coordinating Center testing costs.	Letter of intent: 6/28/22 Proposal: 7/28/22
51.	Warfighter Brain Health Technology Integration (MTEC) W81XWH-15-9-0001	This prototype project aims to create a systems integratory approach to developing an array of brain health medical solutions related to traumatic brain injury and behavioral health to meet the needs of the Warfighter. This prototype project is an innovative business arrangement for a system integrator to identify and rapidly test brain health medical solutions across the continuum of care that aid in the prevention, detection, and treatment of neurotrauma and behavioral health of our U.S. Service Members. https://www.mtec-sc.org/wp-content/uploads/2022/06/MTEC-22-09-BrainHealth-RPP_Amendment-2-1.pdf	Up to $1.7 million for FY22, up to $10 million per year for up to 10 years	Enhanced white paper: 6/17/22
		COMBAT READINESS MEDICAL RESEARCH (1)		
52.	FY22 Combat Readiness Medical, Rapid Development and Translational Research Award (DoD/CDMRP) W81XWH-22-S-CRRP	The intent of the FY22 CRRP RDTRA is to support research that will accelerate the movement of promising ideas into clinical applications, including healthcare products, technologies, and/or practice guidelines. Research under this award mechanism should represent a rapid advancement or innovative "leap ahead" and have the potential for broadly applicable, cross-cutting advances. https://cdmrp.army.mil/funding/crrp	Up to $3.2 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 6/23/22 Invited Application: 9/14/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		COMMUNICATION DISORDERS (1)		
53.	NIDCD Research Opportunities for New Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional) (NIH/NIDCD) RFA-DC-23-001	NIDCD welcomes responsive applications that propose research in communication disorders including those affecting hearing, balance, taste, smell, voice, speech, and language. For applications involving human subjects, applications including individuals from across the lifespan are welcome with populations of interest including both pediatric and adult. https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-23-001.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 7/5/22 Proposal: 8/5/22
		CORONAVIRUS (24)		
54.	NOSI: Research on Alcohol and Coronavirus Disease (COVID-19) within the Mission of NIAAA (NIH/NIAAA) NOT-AA-22-012	This NOSI solicits grant applications that advance understanding of critical interactions between alcohol use, SARS-CoV-2, and COVID-19. A central focus is research that can improve public health by informing responses to the evolving COVID-19 pandemic and its consequences. https://grants.nih.gov/grants/guide/notice-files/NOT-AA-22-012.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 3/6/24
55.	NOSI: Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities (NIH) NOT-HD-22-002	The purpose of this funding opportunity is to provide an avenue for researchers to pursue funding to conduct research addressing these and other emerging and existing COVID-related issues among pregnant and lactating people, infants, children and adolescents, and individuals with physical and/or intellectual disabilities. The goal of this NOSI is to not replace or compete with the various COVID-related funding opportunities currently available. Instead, the purpose is to complement them by offering a funding opportunity to address key issues in a most timely manner not currently covered by available COVID-related funding announcements among these populations. https://grants.nih.gov/grants/guide/notice-files/NOT-HD-22-002.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 6/6/24
56.	NOSI: Social, Behavioral, and Economic Impact of COVID-19 in Underserved and Vulnerable Populations (NIH) NOT-MH-21-330	There are 6 grants within this NOSI, which highlights interest in research to strengthen the understanding and response to the COVID-19 pandemic and help us prepare more effectively for future public health emergencies. The purpose of this Notice is to 1) emphasize the roles and impacts of interventions, and 2) encourage the leveraging of existing large-scale data sources with broad population coverage to improve prediction of various mitigation efforts on transmission reduction and on social and economic impacts, and assess the downstream health and healthcare access effects. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-21-330.html	Dependent on proposal and award, for up to 5 years	Multiple deadlines; NOSI open through 9/8/24

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CORONAVIRUS		
57.	Urgent Award: COVID-19 Mental Health Research (R01 Clinical Trial Required/Optional) (NIH/NIMH) PAR-22-112 PAR-22-113	These FOAs aim to address urgent, time-sensitive mental health research questions related to COVID-19. Research supported will improve public health in the near term by informing responses to the current pandemic. All research is anticipated to focus on particularly vulnerable populations based on existing evidence of increased mental health symptoms and illness and preexisting health disparities. https://grants.nih.gov/grants/guide/pa-files/PAR-22-112.html https://grants.nih.gov/grants/guide/pa-files/PAR-22-113.html	Up to $750,000 per year, for up to 3 years	Letter of intent: 7/25/22 Proposal: 8/25/22
		CYBERSECURITY (1)		
58.	Human Networks and Data Science (HNDS) (NSF) NSF 22-505	HNDS research will identify ways in which dynamic, distributed, and heterogeneous data can provide novel answers to fundamental questions about individual and group behavior. HNDS has two tracks: (1) Human Networks and Data Science – Infrastructure (HNDS-I) and (2) Human Networks and Data Science – Core Research (HNDS-R). https://www.nsf.gov/pubs/2022/nsf22505/nsf22505.htm	Up to $1.2 million	Proposal: 7/14/22 (HNDS-R) 2/2/23 (HNDS-I)
		DARPA (1)		
59.	Biological Technologies BAA (DoD/DARPA) HR001122S0034	BTO's research investment portfolio includes combating pandemic disease, innovative physiological interventions, human performance and warfighter readiness, and deep exploration of changing ecologies and environments for improving U.S. capabilities and resilience. BTO is interested in submissions related to the following topic areas: Human Performance, Materials, Sensors, Processing, Biosecurity, Biomedical, and Biodefense https://sam.gov/opp/dfe93a5637fc419a8ea392ee949f9c79/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis until 4/20/23
		DEFENSE THREAT REDUCTION AGENCY (1)		
60.	Research and Development Innovations Broad Agency Announcement (DoD/DTRA) HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation (RDT&E) priorities across three interrelated thrust areas derived from the 2019 DTRA Strategic Plan for RDT&E (plan available at https://www.dtra.mil/): • Understand the environment, threats, and vulnerabilities • Control, defeat, disable, and dispose of threats • Safeguard the force and manage consequences https://sam.gov/opp/98f9fec4443f4e5d988d2680d85c97f0/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DISSEMINATION AND IMPLEMENTATION RESEARCH (3)		
61.	Dissemination and Implementation Research in Health (R01/R03/R21 Clinical Trials Vary) (NIH) PAR-22-105 (R01) PAR-22-106 (R03) PAR-22-109 (R21)	These FOAs support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. https://grants.nih.gov/grants/guide/pa-files/PAR-22-105.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-106.html (R03) https://grants.nih.gov/grants/guide/pa-files/PAR-22-109.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $50,000 per year, for up to 2 years (R03) Up to $275,000, for up to 2 years (R21)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R03/R21)
		DOWN SYNDROME (9)		
62.	NOSI: NIH Research Project Grants on Down Syndrome (R01) for the INCLUDE (NIH) NOT-OD-22-123	This NOSI supports applications that are focused on Down syndrome and that meet programmatic objectives for the INCLUDE Project. Sharing of resources and effective communication of outputs of appropriate interest to broader communities are a high priority of the INCLUDE Project. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-123.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/1/25
63.	INCLUDE Clinical Trial Readiness and Development, and Transformative Research (R21/R01 Clinical Trial Not Allowed/R61/R33 Clinical Trial Required) (NIH) RFA-OD-22-007 (R21) RFA-OD-22-009 (R01) RFA-OD-22-010 (R61/R33)	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. These FOAs invite applications to support clinical projects, groundbreaking, exceptionally innovative, original, and/or unconventional research, and clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-007.html (R21) https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-009.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-010.html (R61/R33)	Up to $275,000, for up to 2 years (R21) Dependent upon proposal, for up to 5 years (R01/R61/R33)	Proposal: 7/1/22
64.	Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed) (NIH) RFA-OD-22-008	This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions. Development of approaches, tools, or algorithms appropriate for analyzing data relevant to Down syndrome and facilitating data sharing within the research community through the INCLUDE Data Hub may also be proposed. https://grants.nih.gov/grants/guide/rfa-files/RFA-OD-22-008.html	Up to $100,000 per year, for up to 2 years	Letter of intent: 6/1/22 Proposal: 7/1/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DUCHENNE MUSCULAR DYSTROPHY (2)		
65.	FY22 Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) Translational Research Award (TRA) (DoD/CDMRP) W81XWH-22-DMDRP-IDA W81XWH-22-DMDRP-TRA	Applications for the for the FY22 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that focus on primary pathology of DMD. Therapies that will be efficacious across the life span, particularly in adolescents and adults, are encouraged. Applications for the FY22 DMDRP Translational Research Award must address at least one of the following Focus Areas: Translational and clinical studies, novel interventions, and drug and biologic delivery technologies designed to improve care and quality of life; Assessment of clinical trial tools and outcome measures; and Extension or expansion of existing preclinical translational data in support of a specific therapeutic development path. https://cdmrp.army.mil/funding/dmdrp	Up to $1.35 million, for up to 3 years Dependent on award mechanism	Pre-Application: 8/3/22 Invited proposal: 11/15/22
		ENDOCRINE AND METABOLIC DISEASES (2)		
66.	High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional) (NIH/NIDDK) PAR-22-069	This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment and prevention of diseases within the mission of the NIDDK. https://grants.nih.gov/grants/guide/pa-files/PAR-22-069.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/21/22 Proposal: 11/2/22
67.	Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed) (NIH/NIDDK) PAR-22-111	The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-22-111.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 6/14/22 Proposal: 7/14/22
		ENERGY SCIENCE (1)		
68.	FY 2022 Continuation of Solicitation for the Office of Science Financial Assistance Program (DoE) DE-FOA-0002562	By integrating genome science with advanced computational and experimental approaches, the Division seeks to gain a predictive understanding of living systems, from microbes and microbial communities to plants and ecosystems. This foundational knowledge enables design and reengineering of microbes and plants underpinning a broad clean energy and bioeconomy portfolio. https://www.grants.gov/web/grants/view-opportunity.html?oppId=335970	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (7)		
69.	Educational Hub for Enhancing Diversity in Computational Genomics and Data Science (U24 Clinical Trials Not Allowed) (NIH/NHGRI) RFA-HG-22-002	The intent of this specific funding opportunity is to create a CGDS educational hub which will support activities to increase awareness of CGDS and cloud computing concepts, and address barriers to effective CGDS education. The Hub will coordinate with NIH cloud computing platforms to organize workshops, collect stakeholder input, disseminate materials, evaluate educational opportunities and provide logistical support. https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-22-002.html	Up to $1.8 million per year, for up to 5 years	Letter of intent: 6/27/22 Proposal: 7/27/22
70.	NIH Somatic Cell Genome Editing (SCGE) Consortium Technologies and Assays, IND-enabling Studies, Platform Clinical Trials, and Coordination and Dissemination Center (U01/U19/UG3/UH3/U24 CTs Vary) (NIH Common Fund) RFA-RM-22-014 (U01) RFA-RM-22-015 (U19) RFA-RM-22-016 (UG3/UH3) RFA-RM-22-017 (U24)	The SCGE Program will involve collaborative research by a consortium of grantees with differing expertise to develop, optimize and demonstrate improved candidate genome editing therapeutics as treatments for human disease. Collectively, these initiatives are intended to substantially expand the number of genetic diseases treated by in vivo genome editing, ultimately allowing this technology to achieve its potential as a therapeutic platform to treat genetic disease. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-014.html (U01) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-015.html (U19) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-016.html (UG3/UH3) https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-017.html (U24)	Up to $300,000 per year, for up to 3 years (U01) Dependent upon proposal, for up to 5 years (U19) Up to $24 M, for up to 5 years (UG3/UH3) Up to $2 M per year, for up to 5 years (U24)	Letter of intent: 6/17/22 Proposal: 7/19/22
71.	Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) (NIH Common Fund) RFA-RM-22-024	The overall goal of the IDG Program is to catalyze research in areas of biology that are currently understudied but that have high potential to impact human health by (1) identifying biochemical, cellular, or animal model phenotypes for understudied proteins from druggable gene families, (2) enabling further investigation of those proteins by providing reagents and tools, and (3) generating, maintaining, and facilitating the use of a minable knowledge base. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-024.html	Up to $100,000 per year, for 1 year	Letter of intent: 6/15/22 Proposal: 7/15/22
72.	Agricultural Genome to Phenome Initiative (AG2PI) (USDA/NIFA) USDA-NIFA-OP-009161	Applications must aim to use a competitive process to: (1) develop tools and datasets that can be used across multiple crop species to advance genome engineering for integrated optimization of crop yield and animal feed for improved animal reproduction and nutrition; (2) mitigate environmental impacts from crop and animal production and; (3) encourage development of root stocks that increase carbon capture and can support grain crop covers. https://www.nifa.usda.gov/grants/funding-opportunities/agricultural-genome-phenome-initiative	Up to $1.92 million Cost matching required	Proposal: 7/21/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GLOBAL HEALTH (1)		
73.	FY2022 Development Innovation Ventures (USAID) APS-7200AA22APS00001	DIV sources proposals for innovations that address international development challenges and improve the lives of people living in poverty in developing countries around the world. DIV partners with innovators to save lives, reduce poverty, strengthen democracies, respond to climate change, mitigate the consequences of COVID-19, help people emerge from humanitarian crises, and more. https://www.grants.gov/web/grants/view-opportunity.html?oppId=336301	Up to $15 million, dependent on proposal and availability of funds	Proposals accepted on a rolling basis until 10/31/22
		HEALTH IT (6)		
74.	Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences (DMS/NIGMS) (NIH/NSF) NSF 22-600	This FOA supports fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. https://www.nsf.gov/pubs/2022/nsf22600/nsf22600.htm	Up to $1.2 million, for up to 3 years Dependent upon award mechanism	Proposal: 9/19/22
75.	Leveraging Health Information Technology to Address and Reduce Health Care Disparities (R01 Clinical Trial Optional) (NIH) PAR-22-145	This FOA seeks to support multidisciplinary research that examines the impact of leveraging health IT to reduce disparities in access to care, quality of care, patient-clinician communication, and health outcomes for populations that experience health disparities in the U.S. https://grants.nih.gov/grants/guide/pa-files/PAR-22-145.html	Dependent upon proposal, for up to 5 years	Letter of intent: 9/5/22 Proposal: 10/5/22
76.	NIDCR Small Research Grants for Oral Health Data Analysis and Statistical Methodology Dev (R03 CT Not Allowed) (NIH/NIDCR) PAR-22-160	This FOA supports two types of meritorious research projects: 1) secondary data analyses using existing databases relevant to dental, oral, or craniofacial health or practice; and/or 2) development of statistical methodology necessary for improving methods to analyze existing dental, oral, or craniofacial health data. https://grants.nih.gov/grants/guide/pa-files/PAR-22-160.html	Up to $100,000 per year, for up to 2 years	Proposal: 6/16/22
77.	Demonstration Projects to Promote Use of Interoperable Health Records in Clinical Research (R01 CT Not Allowed) (NIH/NIA) RFA-AG-23-019	This FOA solicits applications for 3-year demonstration projects to study the feasibility of, and develop best practices for, using interoperable health information from older adult research participants. The projects are required to collect medical information from electronic health records (EHRs) shared by participants, combine the information inside of a digital infrastructure, and create approaches to harmonize the data across patients and providers. https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-23-019.html	Up to $750,000 per year, for up to 3 years	Letter of intent: 9/18/22 Proposal: 10/18/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEALTH IT		
78.	BRAIN Initiative: Integration and Analysis of BRAIN Initiative Data (R01 Clinical Trial Not Allowed) (NIH) RFA-MH-22-220	As part of programs of building the informatics infrastructure for the BRAIN Initiative, the FOA supports several different, but related activities. These include modifying existing analysis and visualization tools to deal with BRAIN Initiative data and integrating different types of BRAIN Initiative datasets. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-220.html	Dependent upon proposal, for up to 3 years	Letter of intent: 9/14/22 Proposal: 10/14/22
79.	DataWorks! Challenge (NIH/FASEB)	FASEB and NIH are championing a bold vision of data sharing and reuse in the fields of biological and biomedical research. The DataWorks! Prize fuels this vision with an annual challenge that showcases the benefits of research data management while recognizing and rewarding teams whose research demonstrates the power of data sharing or reuse practices to advance scientific discovery and human health. https://www.herox.com/dataworks	Up to $100,000	Proposal: 7/19/22
		HEALTHCARE DISPARITIES (65)		
80.	NOSI: Increasing Uptake of Evidence-Based Screening in Diverse Populations Across the Lifespan (NIH) NOT-OD-22-106	This NOSI, with 33 linked grants, encourages applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in populations including, but not limited to, those experiencing health disparities and those that are underserved. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-106.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
81.	NOSI: Addressing Evidence Gaps in Screening (NIH) NOT-OD-22-107	This NOSI, with 31 linked grants, aims to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined. https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-107.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
82.	Promoting Organ and Tissue Donation Among Health Disparity Populations (R01 - Clinical Trial Optional) (NIH/NIDDK) RFA-DK-22-003	This FOA aims to stimulate research in the area of organ and tissue donation among health disparity populations. Proposed studies may include studying individual-level factors such as attitudes, beliefs, and behaviors towards organ and tissue donation, as well as the need for transplantation. Studies may include examining the influence of social determinants of health on disparities in organ and tissue donation. https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-003.html	Up to $150,000 per year, for up to 5 years	Letter of intent: 9/27/22 Proposal: 10/27/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HEARING RESTORATION (1)		
83.	FY22 Hearing Restoration Focused Research Award (DoD/CDMRP) W81XWH-22-HRRP-FRA	The FY22 HRRP FRA mechanism is intended to support promising research that accelerates drug discovery and therapeutic development for hearing restoration after military-relevant auditory system injury or accelerates advances in diagnosis of auditory dysfunction in austere environments. https://cdmrp.army.mil/funding/pa/W81XWH-22-HRRP-FRA-GG.pdf	Up to $1.25 million, for up to 3 years Dependent upon award mechanism	Pre-Application: 7/22/22 Invited application: 11/30/22
		HIV/AIDS (15)		
84.	NOSI: Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP) (NIH/NIAID/NIMH) NOT-AI-22-042	This NOSI intends to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of 3 months from either a single dosing or continuous dosing regimen to reflect current state of SR/LA drug market for HIV treatment or prevention. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-042.html	Dependent upon proposal, for up to 5 years	Proposal: 9/7/22
85.	NOSI: Towards Developing a Cure for HBV in HIV/HBV Co-Infection (NIH/NIAID) NOT-AI-22-043	The purpose of this NOSI is to encourage applications for support of innovative basic, translational, and clinical research to identify and address the unique challenges to achieving HBV cure in the presence of HIV. Research on HIV/HBV co-infection relating to the following areas will be encouraged: (1) immunology; (2) virology; and (3) therapeutics. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-043.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
86.	Pre-Announcement: Molecular Dynamics of HIV (R01 Clinical Trial Not Allowed) (NIH/NIAID) NOT-AI-22-051	This FOA will support computational dynamic modeling of molecular complexes regulating the HIV life cycle, immune responses, and therapeutic interventions in HIV/AIDS using existing and new HIV and HIV/host cell structural datasets. https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-051.html	Up to $500,000	Estimated post date: 8/9/22 Estimated proposal date: 12/7/22
87.	Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed) (NIH/NIAID) PAR-22-186	This FOA will support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions used for gender reassignment and their impact on susceptibility to HIV and other STI. https://grants.nih.gov/grants/guide/pa-files/PAR-22-186.html	Up to $275,000, for up to 2 years	Proposal: 12/7/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
88.	Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional) (NIH/NIAID/NIDA/NIMH) RFA-AI-22-024	The goal is to prospectively investigate trajectories of HIV care engagement and viral suppression, as well as the temporal antecedents and multilevel factors that drive changes in care engagement, antiretroviral adherence, and viral suppression. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-024.html	Dependent upon proposal, for up to 5 years	Letter of intent: 7/3/22 Proposal: 8/3/22
89.	A Multi-omics Approach to Immune Responses in HIV Vaccination and Intervention (P01 Clinical Trial Not Allowed) (NIH/NIAID/NIDA) RFA-AI-22-038	This FOA will support multi-disciplinary, multi-component applications proposing the use of omics technologies to advance preventative and/or therapeutic vaccinations, and/or immunomodulatory cure interventions for HIV. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-038.html	Up to $1 million per year, for up to 5 years	Letter of intent: 9/13/22 Proposal: 10/13/22
90.	High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) (NIH/NIDA) RFA-DA-22-040	This FOA invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-040.html	Dependent on proposal, for up to 5 years	Letter of intent: 7/15/22 Proposal: 8/15/22
91.	Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required) (NIH/NIDA) RFA-DA-23-008	Applications responding to this FOA should: (1) implement evidence-based approaches that address the intersection of stimulant use and HIV or (2) develop and test new intervention approaches that can reduce stimulant use, particularly among episodic users, while also reducing HIV risk and/or improving HIV care outcomes. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-008.html	Up to $400,000 per year, for up to 2 years (R61) Dependent upon proposal, for up to 3 years (R33)	Letter of intent: 10/10/22 Proposal: 11/10/22
92.	Pathogenic Mechanisms influencing Blood Brain Barrier function in HIV and Substance Use Disorders (R01 Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-012	This FOA supports research on the effects of HIV and addictive substances, acting independently or synergistically on blood brain barrier (BBB) structure and function and the involvement of these effects in HIV associated neuropathology. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-012.html	Dependent upon proposal, for up to 5 years	Letter of intent: 7/11/22 Proposal: 8/11/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		HIV/AIDS		
93.	NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional) (NIH/NICHD) RFA-HD-23-026	This FOA invites submission of Program Project (P01) applications to support integrated, multi-project research programs that address HIV scientific areas relevant to the NICHD mission as a well-defined, central research focus or objective. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-026.html	Up to $1 million per year, for up to 5 years	Letter of intent: 7/10/22 Proposal: 8/10/22
94.	Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in Primary Care Settings in Health Disparity Populations (R01 - Clinical Trial Required) (NIH/NIMHD/ORWH) RFA-MD-22-009	This initiative will support research projects that examine innovative approaches and strategies to prevent, test and treat HIV among health disparity populations or subgroups within primary care settings located in geographic areas with a high rate of new infections in the US. https://grants.nih.gov/grants/guide/rfa-files/RFA-MD-22-009.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 7/15/22 Proposal: 8/15/22
95.	Understanding the role of Gut Immune dysfunction and Gut Microbiome in pathogenesis of CNS co-morbidities in people living with HIV (R21 CT Not Allowed) (NIH/NIMH) RFA-MH-22-230	This FOA supports studies to investigate mechanisms by which the gut microbiome and gut immune system modulates the brain functions, circuits, neurotransmitters, signaling pathways and synaptic plasticity in the context of HIV and Anti-retroviral therapy. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-230.html	Up to $275,000, for up to 2 years	Letter of intent: 10/18/22 Proposal: 11/18/22
		IMMUNOLOGY & INFECTIOUS DISEASE (9)		
96.	Armed Forces Pest Management Board (DoD/AFPMB) AFPMB-BAA-22-01	The AFPMB is soliciting pre-proposals for original and innovative research designed to develop new interventions for protection of deployed military personnel from diseases caused by arthropod-borne pathogens and to improve control of bed bugs and filth flies. Diseases of significant concern include Lyme disease, malaria, dengue fever and other arboviruses. https://sam.gov/opp/4fa92ea106a84436bce4c20cb6627e23/view	Up to $900,000	White papers accepted on a rolling basis until 10/30/24
97.	NOSI: Achieving Tissue Robustness Through Harnessing Immune System Plasticity (NIH/NIDCR) NOT-DE-22-005	NIDCR announces its interest in encouraging state-of-the-art, systematic research approaches to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations, and to examine immune mechanisms of protection against recurrence of chronic inflammation in response to infectious and autoimmune diseases of dental, oral, and craniofacial (DOC) tissues. https://grants.nih.gov/grants/guide/notice-files/NOT-DE-22-005.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
98.	Understanding the Clinical History of Bacterial STIs to Accelerate Diagnostic and Vaccine Development (R01 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-22-034	This FOA aims to support studies on the clinical history of three sexually transmitted infections (STIs): syphilis, gonorrhea, and chlamydia. Improved understanding of the human immune response after infection through diagnosis and treatment will provide a much-needed knowledge base to accelerate vaccine and diagnostic development. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-034.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 8/12/22 Proposal: 9/12/22
99.	Partnerships for Development of Vaccines Against Select Enteric Pathogens (R01 CT Not Allowed) (NIH/NIAID) RFA-AI-22-037	This FOA aims to solicit research applications for projects focused on advancing development of vaccine candidates against Enterotoxigenic *Escherichia coli* (ETEC), *Salmonella enterica* serotype Paratyphi A, and two *Shigella* species, *Shigella flexneri* and *Shigella sonnei*. https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-037.html	Up to $750,000 per year, for up to 5 years	Letter of intent: 8/14/22 Proposal: 9/14/22
100.	BLUE KNIGHT™ QuickFire Challenge: Next-Generation Preparedness Solutions (HHS/BARDA)	Innovators from across the globe are invited to submit potentially ground-breaking ideas or technologies that aim to enhance preparedness towards future known and unknown infectious disease threats. Solutions must address at least one of the focus areas: Targeting the host response to known and unknown future infectious disease threats; Enabling streamlined manufacturing of therapeutics and/or vaccines; and Leveraging the host microbiome. https://jlabs.jnjinnovation.com/quickfire-challenges/blue-knight-tm-quickfire-challenge-next-generation-preparedness-solutions	Up to $200,000	Proposal: 7/22/22
101.	LymeX Diagnostics Prize (HHS)	LymeX is the world's largest public-private partnership for Lyme disease, fostering collaborative innovation among patients and advocates, academia, nonprofits, industry, and government. As a component of a larger moonshot, LymeX is identifying, developing, and implementing advancements in Lyme disease care. https://www.challenge.gov/?challenge=lymex-diagnostics-prize	Up to $1 million	Proposal: 8/8/22
		LUPUS (3)		
102.	FY22 Lupus Idea Award (IA) Impact Award (IPA) Transformative Vision (TVA) (DoD/CDMRP) W81XWH-22-LRP-TVA W81XWH-22-LRP-IPA W81XWH-22-LRP-IA	The FY22 Lupus Research Program includes three award mechanisms: The Idea Award, the Impact Award, and the Transformative Vision Award. Applications must address one or more of the Focus Areas listed here, appropriate to the award sought. https://cdmrp.army.mil/funding/lrp	Up to $2.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MATERNAL AND PEDIATRIC HEALTH (9)		
103.	Preventing Maternal Mortality: Supporting Maternal Mortality Review Committees (CDC/NCCDPHP) CDC-RFA-DP22-2211	This FOA supports agencies and organizations that coordinate and manage MMRCs to identify and characterize pregnancy-related deaths for preventability, abstract clinical/non-clinical data into a standard data system, conduct informant interviews to inform individual case review, and enter information into a standard data system within 2 years of death. https://www.grants.gov/web/grants/view-opportunity.html?oppId=338449	Up to $600,000, for 1 year	Proposal: 6/20/22
104.	NOSI: IMPROVE Initiative: Implementation Science to Advance Maternal Health and Maternal Health Equity (NIH) NOT-OD-22-125	This NOSI aims to stimulate dissemination and implementation research on innovative approaches built on evidence-based findings from foundational research on factors that contribute to maternal morbidity and mortality (MMM). https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-125.html	Dependent upon proposal and award mechanism	Multiple deadlines; first available due date: 6/5/22
105.	Evidence-Based Clinical Practice Guideline for the Management of Postoperative Pain After Surgeries in Obstetric Patients (U01) CT Not Allowed (FDA/CDER) RFA-FD-22-028	This FOA seeks applications to develop, disseminate, implement, and evaluate an evidence-based Clinical Practice Guideline (CPG) for the management of postoperative pain in obstetric patients who have undergone surgeries, including but not limited to cesarean delivery, vaginal delivery, and appendectomy during pregnancy. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-028.html	Up to $2 million, for up to 3 years	Letter of intent: 6/23/22 Proposal: 8/3/22
106.	Bioprinted Tissue Constructs for Obstetric, Gynecologic, and Pediatric Applications (R01 Clinical Trial Optional) (NIH/NICHD) RFA-HD-23-004	This FOA aims to encourage applications that will utilize 3D bioprinting technologies to develop tissue constructs for long-term use that will adapt to the needs of growing children, and for obstetric and gynecological conditions. The overall goal of this initiative is to promote the clinical translation of bioprinted tissue constructs by helping to identify and working to overcome current barriers to preclinical product development, validation and verification. https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-004.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 6/27/22 Proposal: 7/27/22
107.	Improving Maternal Health through Addressing Endometriosis, Fibroids, and/or Polycystic Ovary Syndrome (HHS/OASH) WH-AST-22-001	The goals of this initiative are to: • Develop a demonstration project that implements and evaluates one or more evidence-based interventions to comprehensively diagnose and treat endometriosis, fibroids, and/or PCOS. • Identify and track evidence-based outcomes to demonstrate improvements in early diagnosis and effective treatment of one or more of these conditions; and • Transition a successful project to sustainability. https://www.grants.gov/web/grants/view-opportunity.html?oppId=335046	Up to $300,000	Proposal: 7/7/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MEDICAL COUNTERMEASURES (1)		
108.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) (DoD/DTRA) W900KK-22-R-0012	DTRA seeks to identify, adopt, and adapt emerging, existing and revolutionary sciences that may demonstrate high payoff potential to Counter-WMD (C-WMD) threats. Current thrust areas include global biosurveillance, biosafety, and biosecurity, and chemical and biological defense. https://sam.gov/opp/da2d0850923340169b5263998efe73f6/view	Up to $1 million per year, for up to 5 years	White papers accepted through 9/30/2024
		MENTAL HEALTH (26)		
109.	NOSI: Research using implementation science to support the delivery of evidence-based practices in community-based mental or general medical healthcare settings (NIH/NIMH/NIDA) NOT-MH-22-170	This NOSI highlights interest in mental health services and implementation science research to support the adoption and sustainability of evidence-based practices (EBPs) in community-based settings that deliver care to people with mental illness. These settings could include, but are not limited to, Certified Community Behavioral Health Clinics (CCBHCs) funded through the Substance Abuse and Mental Health Services Administration (SAMHSA) Certified Community Behavioral Health Clinic-Expansion (CCBHC-E) grant program. https://grants.nih.gov/grants/guide/notice-files/NOT-MH-22-170.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 5/8/25
110.	Innovative Pilot Mental Health Services Research Not Involving Clinical Trials (R01/R34 Clinical Trial Not Allowed) (NIH/NIMH) PAR-21-316 (R01) PAR-22-082 (R34)	These FOAs encourage innovative pilot research that will inform and support the delivery of high-quality, continuously improving mental health services to benefit the greatest number of individuals with, or at risk for developing, a mental illness. This announcement invites applications for non-clinical trial pilot projects that address NIMH strategic priorities to strengthen the public health impact of NIMH-supported research. https://grants.nih.gov/grants/guide/pa-files/PAR-21-316.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-082.html (R34)	Dependent on proposal, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R34)
111.	Mood and Psychosis Symptoms during the Menopause Transition (R01/21 Clinical Trial Optional) (NIH/NIMH) PAR-22-035 (R01) PAR-22-036 (R21)	These FOAs encourage applications that will advance mechanistic and translational research on the onset and worsening of mood and psychotic disorders during the menopausal transition. In particular, NIMH seeks research that will advance understanding of the underlying neurobiological and behavioral mechanisms of mood disruption and psychosis during the menopausal transition and that will identify novel targets for future mental health interventions or prevention efforts. https://grants.nih.gov/grants/guide/pa-files/PAR-22-035.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-036.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Proposal: 10/5/22 (R01) Proposal: 6/16/22 (R21)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
112.	National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01/U19 Clinical Trial Optional) (NIH/NIMH/NIAAA) PAR-22-143 (U01) PAR-22-144 (U19)	Studies appropriate for these FOAs will develop pharmacologic and neuromodulatory tools for basic and clinical research on mental health disorders or AUD; develop and validate tools in support of experimental therapeutic studies of innovative candidates for mental disorders or AUD; and support early-stage human studies to rapidly assess the safety, tolerability, and pharmacodynamics of promising drug candidates/devices and new indications for novel IND-ready agents or IDE-ready devices for the treatment of mental disorders or AUD. https://grants.nih.gov/grants/guide/pa-files/PAR-22-143.html (U01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-144.html (U19)	Dependent upon proposal, for up to 5 years	Proposal: 6/27/22
113.	Laboratories to Optimize Digital Health (R01 Clinical Trial Required) (NIH/NIMH) PAR-22-154	This FOA is intended to support the development of digital health test beds that leverage well-established digital mental health platforms/infrastructure to rapidly refine and optimize existing evidence based digital health interventions and conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations. https://grants.nih.gov/grants/guide/pa-files/PAR-22-154.html	Dependent upon proposal, for up to 4 years	Letter of intent: 9/5/22 Proposal: 10/5/22
114.	Pilot Practice-based Research for Primary Care Suicide Prevention (R34 Clinical Trial Optional) (NIH/NIMH) RFA-MH-22-120	This FOA is intended to support rigorous evaluations of factors that impact or account for the effectiveness of existing suicide prevention practices and/or pilot clinical trials aimed at developing, optimizing, and pilot testing scalable patient-, provider-, and systems- level interventions and service delivery approaches for intervening at key intercepts in the chain of care. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-120.html	Up to $450,000, for up to 3 years	Proposal: 6/21/22
115.	Understanding Suicide Risk and Protective Factors among Black Youth (R01/R21 Clinical Trial Not Allowed) (NIH/NIMH) RFA-MH-22-140 (R01) RFA-MH-22-141 (R21)	These FOAs encourage research that is designed to identify neurobiological, behavioral, social, and structural/systemic mechanisms underlying risk and protective factors for suicide among Black youth, with consideration for identification of novel targets for future development of prevention and intervention efforts. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-140.html (R01) https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-141.html (R21)	Dependent upon proposal, for up to 5 years (R01) Up to $275,000, for up to 2 years (R21)	Letter of intent: 9/19/22 Proposal: 10/19/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		MENTAL HEALTH		
116.	Expanding Prevention Strategies for Mental Disorders in Mobile Populations in Humanitarian Crises (R34 Clinical Trial Optional) (NIH/NIMH) RFA-MH-22-180	NIMH seeks to fund research focused on understanding the role human mobility has on mental health outcomes and developing and testing culturally appropriate preventive interventions for mental disorders that may develop during all phases of migration. This FOA seeks to develop assessment tools, preventive interventions, and implementation approaches to improve mental health outcomes in mobile populations. https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-22-180.html	Up to $450,000, for up to 3 years	Letter of intent: 9/25/22 Proposal: 10/25/22
117.	Mission Daybreak (DoD/VA)	Suicide is preventable, and we all have a part to play. A diversity of solutions will only be possible if a diversity of solvers — including researchers, technologists, advocates, clinicians, health innovators, Veterans, and service members — answer the call to collaborate and share their expertise. https://www.missiondaybreak.net/	Up to $3 million	Proposal: 7/8/22
		MILITARY BURN (2)		
118.	FY22 Military Burn Clinical Translational Research Award (CTA) Technology/Therapeutic Development Award (TTDA) (DoD/CDMRP) W81XWH-22-MBRP-CTRA W81XWH-22-MBRP-TTDA	The FY22 Military Burn Research Program includes two award mechanisms: The Clinical Tranlational Research Award and the Technology/Theraputic Development Award. Applications to the FY22 MBRP must address one or more of the following Focus Areas: • Atypical Burns • Burn Injury During Mass Casualty • Burn injury related complications https://cdmrp.army.mil/funding/mbrp	Up to $2.21 million, for up to 4 years Dependent upon award mechanism	Pre-application: 6/27/22 Invited proposal: 10/11/22
		MULTIPLE SCLEROSIS (1)		
119.	FY22 Multiple Sclerosis Early Investigator Research Award (EIRA) Clinical Trial Award (CTA) Investigator-Initiated Research Award (IIRA) Exploration-Hypothesis Development Award (EHDA) (DoD/CDMRP) W81XWH-22-MSRP-EIRA W81XWH-22-MSRP-CTA W81XWH-22-MSRP-IIRA W81XWH-22-MSRP-EHDA	The FY22 MSRP supports innovative and impactful research that addresses fundamental issues and gaps in Multiple Sclerosis (MS). All four awards planned for FY2022 have been updated: Clinical Trial Award, Early Investigator Research Award, Exploration - Hypothesis Development Award, Investigator-Initiated Research Award. Applications must address focus areas specific to each award. https://cdmrp.army.mil/funding/msrp	Up to $4.5 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/23/22 Invited Application: 10/3/22 (CTA, IIRA, EHDA) Pre-Application: 8/2/22 Proposal: 10/3/22 (EIRA)

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION (2)		
120.	Small Business Innovation Research Program Phase I (SBIR/STTR Phase I) (NSF) NSF 22-551	The NSF SBIR and STTR programs focus on transforming scientific discovery into products and services with commercial potential and/or societal benefit. Unlike fundamental or basic research activities that focus on scientific and engineering discovery itself, the NSF SBIR program supports the creation of opportunities to move fundamental science and engineering out of the lab and into the market or other use at scale, or startups and small businesses representing "deep technology ventures." The programs fund research and development, and are designed to provide non-dilutive funding and entrepreneurial support at the earliest stages of company and technology development. The required Project Pitch allows startups and small businesses to get quick feedback at the start of their application for Phase I funding. Click here for project pitch details and for the full list of topics click here. https://beta.nsf.gov/funding/opportunities/small-business-innovation-research-program-phase-i-sbirsttr-phase-i	Up to $275,000 for up to 1 year	Project pitches accepted on a rolling basis. Submission window for invited proposals: 7/1/22 to 10/26/22
		NATIONAL VIRTUAL BIOTECHNOLOGY LABORATORY (1)		
121.	Opportunities from the National Virtual Biotechnology Laboratory (NVBL) (DOE)	NVBL is a consortium of National laboratories that addresses key challenges in responding to the COVID-19 threat. Examples include developing innovations in testing capabilities, identifying targets for medical therapeutics, providing epidemiological and logistical support, and addressing supply chain bottlenecks. https://science.osti.gov/nvbl	Dependent upon solicitation and proposal	N/A
		NEUROFIBROMATOSIS (7)		
122.	FY22 Neurofibromatosis Clinical Trial Award (CTA) Exploration- Hypothesis Development Award (EHDA) Early Investigator (EIRA) Investigator- Initiated (IIRA) New Investigator Award (NIA) Synergistic Idea Award (SIA) (DoD/CDMRP) W81XWH-22-NFRP-CTA W81XWH-22-NFRP-EHDA W81XWH-22-NFRP-EIRA W81XWH-22-NFRP-IIRA W81XWH-22-NFRP-NIA W81XWH-22-NFRP-SIA	Applications submitted to the six award mechanisms included in the FY22 Neurofibramatosis Research Program must address one or more of the following Areas of Emphasis: • Neurofibromatosis (NF) Type 2-related areas • Biomarker discovery, utility, development, and validation • Non-tumor manifestations • Heterogeneity of NF-related tumors • Novel disease and treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics, or similar approaches • Preclinical efficacy studies • Target identification, drug discovery • Nutritional, environmental, and other modifiers of NF • Health services research https://cdmrp.army.mil/funding/nfrp	Up to $2 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/30/22 Proposal: 7/21/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NEUROFIBROMATOSIS		
123.	Biology and Therapeutic Development for Cutaneous Neurofibromas (NTAP)	This RFA supports therapeutics for the peripheral nerve tumors that afflict people with Neurofibromatosis Type 1 (NF1). http://www.n-tap.org/nf1-and-cutaneous-neurofibroma/	Up to $1 million, for up to 3 years	Letter of intent: 8/5/22 Proposal: 9/2/22
		NIH COMMON FUND (1)		
124.	NIH Director's Transformative Research Awards (R01 Clinical Trial Optional) (NIH Common Fund) RFA-RM-22-020	This FOA supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-020.html	Dependent upon proposal, for up to 5 years	Proposal: 9/1/22
		OFFICE OF NAVAL RESEARCH (1)		
125.	Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology (DoD/Navy) N00014-22-S-B001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://www.onr.navy.mil/en/work-with-us/funding-opportunities/announcements	Dependent upon proposal	Proposals accepted on a rolling basis until 9/30/22
		PAIN MANAGEMENT (3)		
126.	HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed) (NIH) RFA-NS-22-018	This FOA supports multidisciplinary groups of researchers to conduct collaborative, team-based science utilizing cutting-edge technologies and approaches and large-scale, high throughput tissue and single-cell analysis on primary human tissues involved in human pain processing. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-018.html	Up to $1.5 million per year, for up to 5 years	Letter of intent: 9/11/22 Proposal: 10/11/22
127.	HEAL Initiative: Discovery of Biomarkers and Biomarker Signatures to Facilitate Clinical Trials for Pain Therapeutics (UG3/UH3 Clinical Trial Optional) (NIH) RFA-NS-22-050	This FOA aims to promote the discovery of candidate biomarkers or biomarker signatures for pain that can be used to facilitate the testing of non-opioid pain therapeutics in Phase II clinical trials. The biomarkers or biomarker signature will be developed through clinical research specifically focused on the identification of pain biomarkers or biosignatures that predict and/or monitor response to pain therapeutics. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-050.html	Up to $500,000 per year, for up to 2 years (UG3) Up to $1.5 million per year, for up to 3 years (UH3)	Letter of intent: 9/13/22 Proposal: 10/13/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PAIN MANAGEMENT		
128.	HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed) (NIH) RFA-NS-22-052	The goal of this FOA is to support interdisciplinary team-based research projects to develop assays, conduct screening and early optimization work followed by pharmacokinetic, pharmacodynamic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development. https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-22-052.html	Up to $1.5 million per year, for up to 5 years	Letter of intent: 9/11/22 Proposal: 10/11/22
		PARKINSON'S DISEASE (3)		
129.	FY22 Parkinson's Research Program (PRP) Early Investigator Research Award (EIRA) Investigator-Initiated Research Award (IIRA) Synergistic Idea Award (SIA) (DoD/CDMRP) W81XWH-22-PRP-EIRA W81XWH-22-PRP-IIRA W81XWH-22-PRP-SIA	Applications submitted to the three award mechanisms included in the FY22 Parkinson's Research Program must address one or more of the following Focus Areas: • Biological mechanisms and biomarkers of non-motor symptoms that could lead to the development of treatments for PD. Non-motor symptoms of interest include: Cognitive, Psychiatric, Sleep, Autonomic, and Sensory dysfunctions; Fatigue. • Biological mechanisms and biomarkers of non-pharmacological interventions for non-motor symptoms in PD. https://cdmrp.army.mil/funding/prp	Up to $3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 8/16/22 Proposal: 9/1/22
		PATIENT-CENTERED RESEARCH (7)		
130.	Open Competition PFA: Implementation of Findings from PCORI's Major Research Investments -- Cycle 2 2022 (PCORI)	For the Cycle 2 2022 PFA, PCORI has identified the following four areas of eligible evidence: Obesity Treatment in Primary Care Settings; Nonsurgical treatment options can improve or eliminate symptoms for women with urinary incontinence (UI); Several kinds of therapy and medicines can reduce or stop symptoms for people with PTSD; The use of narrow-spectrum versus broad-spectrum antibiotics to treat children's acute respiratory tract infections (ARTIs). https://www.pcori.org/funding-opportunities/announcement/open-pcori-funding-announcement-implementation-findings-pcoris-research-investments-cycle-2-2022	Up to $2.5 million, for up to 3 years	Letter of intent: 6/21/22 Proposal: 8/31/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
131.	Pre-Announcement: Science of Engagement PCORI Funding Announcement (PCORI)	This PFA will fund studies that build an evidence base on engagement in research, including: • Measures to capture structure/context, process, and outcomes of engagement in research • Techniques that lead to effective engagement in research • How these techniques should be modified and resourced for different contexts, settings, and communities to ensure equity in engagement and research • How engagement supports successful research, thereby advancing PCORI's National Priorities for Health. https://www.pcori.org/funding-opportunities/announcement/science-engagement-pcori-funding-announcement	Up to $1.5 million, for up to 3 years Dependent upon award mechanism	System opens: 7/12/22 Letter of intent: 8/9/22 Proposal: 11/15/22
132.	Pre-Announcement: Phased Large Awards for Comparative Effectiveness Research -- Cycle 3 2022 (PCORI)	This PFA invites applications for high-quality comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, caregivers, clinicians, and stakeholders across the health and healthcare community and for which there is insufficient evidence. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-cycle-3-2022	TBD	System opens: 9/7/22 Letter of intent: 10/4/22 Proposal: 1/10/23
133.	Pre-Announcement: Engagement Award: Stakeholder Convening Support -- October 2022 Cycle (PCORI)	The Engagement Award: Stakeholder Convening Support funding opportunity provides support to organizations and communities to hold multi-stakeholder convenings, meetings, and conferences that include a combination of patients, caregivers, researchers, clinicians, purchasers, payers, health system leaders, and/or other stakeholders. Convenings should be designed with the active collaboration and partnership of patients, community groups, and/or other stakeholder organizations. https://www.pcori.org/funding-opportunities/announcement/engagement-award-stakeholder-convening-support-october-2022-cycle	Up to $100,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23
134.	Pre-Announcement: Engagement Award: Dissemination Initiative -- October 2022 Cycle (PCORI)	The Engagement Award: Dissemination Initiative funding opportunity aims to support projects that help organizations and communities plan for or actively bring pertinent PCORI-funded research findings to their specific audiences, including relevant patients, clinicians, communities, and others, in ways that will command their attention and interest and encourage use of this information in their healthcare decision making. https://www.pcori.org/funding-opportunities/announcement/engagement-award-dissemination-initiative-october-2022-cycle	Up to $250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED RESEARCH		
135.	Pre-Announcement: Engagement Award: Capacity Building -- October 2022 Cycle (PCORI)	The Engagement Award: Capacity Building opportunity funds projects that build communities prepared to participate in PCOR/CER. These awards support organizations with strong ties to patients, caregivers, clinicians, and other stakeholders who have a connection to a research focus area and seek to better equip stakeholders to engage as partners in PCOR/CER. https://www.pcori.org/funding-opportunities/announcement/engagement-award-capacity-building-october-2022-cycle	Up to $250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/11/23
136.	Pre-Announcement: Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER -- October 2022 Cycle (PCORI)	The Engagement Award: Building Capacity for Small Organizations to Engage in PCOR/CER funding opportunity will support two-year projects that help small organizations and their communities build capacity and skills to take part in the PCOR/CER process. https://www.pcori.org/funding-opportunities/announcement/engagement-award-building-capacity-small-organizations-engage-pcorcer-october-2022-cycle	Up to $250,000, for up to 2 years	System opens: 7/19/22 Letter of intent: 9/29/22 Proposal: 1/24/23
		PEER REVIEWED ORTHOPAEDIC (3)		
137.	FY22 Peer Reviewed Orthopaedic Applied Research Award (ARA) Clinical Trial Award (CTA) Clinical Translational Research Award (CTRA) (DoD/CDMRP W81XWH-22-PRORP-ARA W81XWH-22-PRORP-CTA W81XWH-22-PRORP-CTRA	Applications submitted to the three awards within the FY22 PRORP must address one or more of the following Focus Areas: • Compartment Syndrome and/or Reperfusion Injury • Composite Tissue Regeneration • Limb Stabilization and Protection • Osseointegration • Prostheses and Orthoses • Retention Strategies • Tissue Regeneration Therapeutics • Translation of Early Findings https://cdmrp.army.mil/funding/prorp	Up to $3 million, for up to 4 years Dependent upon award mechanism	Pre-Application: 6/16/22 Invited proposal: 9/13/22
		PRENATAL AND PEDIATRIC HEALTH (3)		
138.	NOSI: Tools to Enhance the Study of and Disease Mechanisms of Prenatal and Pediatric Hydrocephalus (NIH/NINDS) NOT-NS-23-003 NOT-NS-23-004	Topics of interest include 1) novel or significantly improved cell and/or animal models of hydrocephalus; and 2) novel methods and/or innovative technologies to accelerate the understanding of prenatal and/or pediatric hydrocephalus. Cutting-edge and/or high-risk applications are strongly encouraged. https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-003.html https://grants.nih.gov/grants/guide/notice-files/NOT-NS-23-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 12/10/25

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		RARE DISEASES (2)		
139.	Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03/R21 Clinical Trial Not Allowed) (NIH/NCATS/NICHD) PAR-22-100 (R03) PAR-22-101 (R21)	The initiative seeks applications that are intended to facilitate rare diseases research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials. https://grants.nih.gov/grants/guide/pa-files/PAR-22-100.html (R03) https://grants.nih.gov/grants/guide/pa-files/PAR-22-101.html (R21)	Up to $50,000 per year, for up to 2 years (R03) Up to $275,000, for up to 2 years (R21)	Letter of intent: 9/17/22 Proposal: 10/17/22
		RECONSTRUCTIVE TRANSPLANT (4)		
140.	Pre-Announcement: FY22 Reconstructive Transplant Research Program (RTRP) (DoD/CDMRP)	Applications submitted to the FY22 RTRP must address one or more of the Focus Areas appropriate to each award. Four awards are anticipated: Investigator-Initiated Research Award; Advanced Technology Development Award; Concept Award; and Clinical Network Award. https://cdmrp.army.mil/pubs/press/2022/22rtrppreann	Up to $10 million, for up to 4 years Dependent upon award mechanism	TBD
		REPURPOSING THERAPIES (1)		
141.	2022 ReGRoW: Repurposing Grants for the Rest of the World (CWR)	This RFP is seeking clinical repurposing research to address any unsolved disease facing patients in LMICs. CWR is interested in building capacity for clinical research in LMICs and in finding available and affordable treatments for patients in LMICs through repurposing research. https://www.cureswithinreach.org/wp-content/uploads/2022/03/CWR-ReGRoW-2022-Clinical-Repurposing-Research-RFP.pdf	Up to $50,000	Proposal: 6/20/22
		SMALL BUSINESS DEVELOPMENT (5)		
142.	PHS 2022-2 Omnibus Solicitation of the NIH/CDC/FDA for (Parent SBIR/STTP [R43/R44/R41/R42] Clinical Trials Vary) (NIH/CDC/FDA) PA-22-176 PA-22-177 PA-22-178 PA-22-179	US small businesses that have the research capabilities and technological expertise to contribute to the R&D mission(s) identified in these FOAs are encouraged to submit SBIR/STTP grant applications in response to identified topics (see PHS 2022-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA). https://grants.nih.gov/grants/guide/pa-files/PA-22-176.html https://grants.nih.gov/grants/guide/pa-files/PA-22-177.html https://grants.nih.gov/grants/guide/pa-files/PA-22-178.html https://grants.nih.gov/grants/guide/pa-files/PA-22-179.html	Up to $275,766, for up to 2 years (Phase I) Up to $1.8 million, for up to 3 years (Phase II)	Proposal: 9/5/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
143.	Joint DoD SBIR 22.2 / STTR 22.B (DoD)	The objectives of the DoD SBIR Program include stimulating technological innovation, strengthening the role of small business in meeting DoD research and development needs, fostering and encouraging participation by minority and disadvantaged persons in technological innovation, and increasing the commercial application of DoD-supported research or research and development results. https://rt.cto.mil/rtl-small-business-resources/sbir-sttr/	Dependent upon proposal and award mechanism	Proposal: 6/15/22
		SUBSTANCE USE DISORDER (24)		
144.	NOSI: High Priority Areas in Integrative Neuroscience Branch in the Division of Neuroscience and Behavior (NIH/NIDA) NOT-DA-22-058	Research supported by the Branch covers: 1) the regulation and plasticity of neurotransmitter and neuromodulatory systems induced by chronic or intermittent exposure to, and/or withdrawal from, addictive substances, 2) the study of substance-induced neurotoxicity, 3) neuron-glia interactions and their modification by substance use and SUD 4) neuroendocrine modulation of neural systems in relation to substance use and SUD , and 5) neuroimmune modulation of the brain including the influences of neuroAIDS and substance-induced neuroinflammation. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-22-058.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 1/8/26
145.	NOSI: High Priority Areas in Genetics, Epigenetics, and Developmental Neuroscience Branch in the Division of Neuroscience and Behavior (NIH/NIDA) NOT-DA-23-004	Research areas of general interest include but are not limited to: human and animal genetic studies of vulnerability to addiction, molecular genetics and genomic studies related to the response to addictive drugs, epigenetic mechanisms of substance use disorders and addiction, cell biology studies of addiction, development of neural pathways and brain structures that mediate SUDs and addiction and bioinformatic approaches to better model the genetics of SUDs, including data integration, methods development, and machine learning. https://grants.nih.gov/grants/guide/notice-files/NOT-DA-23-004.html	Dependent upon proposal and award mechanism	Multiple deadlines; NOSI open through 9/8/25
146.	Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44/UT1/UT2 Clinical Trial Optional) (NIH/NIAAA) PAR-22-102 (U43/U44) PAR-22-103 (UT1/UT2)	These FOAs support SBIR and STTR applications that propose the development of therapeutic agents for the treatment of AUD and/or AAOD. As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. https://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html (U43/U44) https://grants.nih.gov/grants/guide/pa-files/PAR-22-103.html (UT1/UT2)	Phase I: Up to $1 million per year, for up to 2 years Phase II: Up to $1.5 million per year, for up to 3 years	Letter of intent: 11/5/22 Proposal: 3/28/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
147.	Alcohol Health Services Research and Treatment and Recovery Research (R01/R34 Clinical Trial Optional/Required) (NIH/NIAAA) PAR-22-156 (R01) PAR-22-157 (R34) PAR-22-158 (R01) PAR-22-159 (R34)	PAR-22-156 and PAR-22-157 will broadly focus on closing the treatment gap for individuals with AUD. PAR-22-158 and PAR-22-159 will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery. https://grants.nih.gov/grants/guide/pa-files/PAR-22-156.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-157.html (R34) https://grants.nih.gov/grants/guide/pa-files/PAR-22-158.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-159.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Letter of intent: 9/5/22 Proposal: 10/5/22 (R01) Letter of intent: 9/16/22 Proposal: 10/16/22 (R34)
148.	Behavioral & Integrative Treatment Development Program (R01/R34 Clinical Trial Optional) (NIH/NIDA) PAR-22-182 (R01) PAR-22-183 (R34)	These FOAs encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, rehabilitative, skills training, counseling, family, and exercise therapies. https://grants.nih.gov/grants/guide/pa-files/PAR-22-182.html (R01) https://grants.nih.gov/grants/guide/pa-files/PAR-22-183.html (R34)	Dependent upon proposal, for up to 5 years (R01) Up to $450,000, for up to 3 years (R34)	Letter of intent: 7/10/22 Proposal: 8/10/22
149.	Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1-Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-23-014	The Avenir Award for Chemistry and Pharmacology of Substance Use Disorders program will support early stage investigators proposing transformative studies that open new avenues of research in the area of chemistry and pharmacology of addictive substances, substance use disorders and addiction. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-014.html	Up to $500,000 per year, for up to 5 years	Letter of intent: 7/11/22 Proposal: 8/11/22
150.	Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trial Not Allowed) (NIH/NIDA) RFA-DA-23-015	This FOA will support projects proposing mechanistic studies that will transform our understanding of polysubstance use in addiction. These hypothesis-based, exploratory projects may investigate mechanisms of polysubstance use at the behavioral, cognitive, cellular, circuit, genetic, epigenetic, pharmacological and/or computational levels. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-015.html	Up to $350,000 per year, for up to 5 years	Letter of intent: 10/14/22 Proposal: 11/14/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SUBSTANCE USE DISORDER		
151.	Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional) (NIH/NIDA) RFA-DA-23-021	This FOA encourages SBIR grant applications proposing research projects, directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from OUD and/or StUD. Applications received under this FOA may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics) and (2) medical therapeutic and diagnostic devices, including software as a medical device. https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html	Up to $320,000, for up to 1 year (Phase I) Up to $2.5 million, for up to 3 years (Phase II)	Letter of intent: 7/15/22 Proposal: 8/15/22
152.	Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed) (NIH) RFA-TR-22-011	This FOA aims to support early-stage research to increase our knowledge of understudied proteins of the druggable proteome and enable the scientific community to identify and validate new targets for pain, opioid use disorder (OUD), and/or overdose (OD). These awards will support generation of preliminary data and tools around eligible understudied protein(s) identified by the HEAL Program with the intent of elucidating the function of these proteins in the context of pain, OUD and/or OD and obtaining sufficient preliminary data and/or research resources for subsequent R01 applications and/or drug discovery/development projects. https://grants.nih.gov/grants/guide/rfa-files/RFA-TR-22-011.html	Up to $275,000, for up to 2 years	Letter of intent: 8/7/22 Proposal: 8/22/22
153.	Reducing Maternal Deaths Due To Substance Use Disorder (HHS/OASH) WH-AST-22-003	This notice solicits applications for projects designed to strengthen perinatal and postnatal support structures for patients with SUD and reduce deaths during the perinatal and postpartum time period. https://www.grantsolutions.gov/gs/preaward/previewPublicAnnouncement.do?id=96146	Up to $300,000 per year, for up to 3 years	Proposal: 7/11/22
		THERAPEUTICS (1)		
154.	Evidence-Based Clinical Practice Guideline for the Safe Tapering of Benzodiazepines (U01) Clinical Trials Not Allowed (FDA) RFA-FD-22-027	The FDA seeks applications to develop, disseminate, implement, and evaluate an evidence-based Clinical Practice Guideline (CPG) for the safe tapering of benzodiazepines. https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-22-027.html	Up to $2 million, for up to 3 years	Letter of intent: 6/23/22 Proposal: 8/3/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		TUBEROUS SCLEROSIS COMPLEX (3)		
155.	FY22 Tuberous Sclerosis Complex Research Program Clinical Translational Research Award (CTRA) Exploration – Hypothesis Development Award (EHDA) Idea Development Award (IDA) (DoD/CDMRP) W81XWH-22-TSCRP-CTRA W81XWH-22-TSCRP-EHDA W81XWH-22-TSCRP-IDA	Applications submitted to the FY22 TSCRP Program must address one or more of the following focus areas, appropriate to each award mechanism: • Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact • Strategies for eradicating tumors or other pathogenic lesions associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM) • Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures https://cdmrp.army.mil/funding/tscrp	Up to $1 million, for up to 3 years Dependent upon award mechanism	Pre-application: 6/30/22 Proposal: 7/28/22
		US AIR FORCE ACADEMY (1)		
156.	Research Interests of the United States Air Force Academy (DoD/Air Force) USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/web/grants/view-opportunity.html?oppId=330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis
		US ARMY COMBAT CAPABILITIES DEVELOPMENT COMMAND (1)		
157.	US Army Combat Capabilities Development Command Broad Agency Announcement (DoD/Army) W911QY20R0022	Broad Agency Announcement Solicitation for the US Army Combat Capabilities Development Command - Soldier Center (CCDC-SC). Please see the BAA solicitation document for the submission instructions and areas of interest. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327285	Dependent upon proposal	Proposals accepted on a rolling basis until 2/28/25
		US ARMY RESEARCH INSTITUTE (2)		
158.	U.S. Army Research Institute for the Behavioral and Social Sciences (ARI) Broad Agency Announcement for Basic, Applied, and Advanced Research (DoD/Army) W911NF-18-S-0005	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://www.grants.gov/web/grants/view-opportunity.html?oppId=304462	Dependent upon proposal	Proposals accepted on a rolling basis until 4/29/23 Full proposal required

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		US ARMY RESEARCH INSTITUTE		
159.	Army Research Institute for the Behavioral and Social Sciences BAA for Basic Scientific Research, Foundational Science Research Unit (2021-2022) (DoD/Army) W911NF-21-S-0007	The U.S. Army Research Institute for the Behavioral and Social Sciences is the Army's lead agency for the conduct of research, development, and analyses for the improvement of Army readiness and performance via research advances and applications of the behavioral and social sciences that address personnel, organization, training, and leader development issues. Programs funded under this BAA include basic research that can improve human performance and Army readiness. https://www.grants.gov/web/grants/view-opportunity.html?oppId=331391	Dependent upon proposal	Proposals accepted until: 8/4/22
		US MILITARY ACADEMY (1)		
160.	United States Military Academy Broad Agency Announcement (DoD/USMA) W911NF-20-S-0008	This BAA identifies topics of interest to USMA departments, directorates, and research centers and institutes. Proposals are sought for cutting-edge innovative research that could produce discoveries with a significant impact to enable new and improved Army technologies and related operational capabilities and related technologies. https://www.grants.gov/web/grants/view-opportunity.html?oppId=325932	Dependent upon proposal	Proposals accepted on a rolling basis
		US NAVY (3)		
161.	FY22 Naval Air Warfare Center Aircraft Division (NAWCAD) Office-Wide Broad Agency Announcement (DoD/Navy) N00421-22-S-0001	NAWCAD has identified the research needed to address the challenges, problems, and future technology needs of the Warfighter. Research Opportunity Areas of Interest include: AI/ML; Data Science & Visualization; Cyber; Quantum; Secure Communications & Networks; Warfare Analysis; Readiness & Sustainment; Materials & Aircraft Structures; Aeromechanics; Mechanical Systems; Human Systems; Support Equipment; and Systems Engineering. https://sam.gov/opp/daa2293493bd43f69bf1ad9b716f7bb5/view	Dependent upon proposal	White papers accepted on a rolling basis until 6/1/23
162.	Broad Agency Announcement for Innovative Environmental Technologies and Methodologies (DoD/Navy) N3943022S2401	This announcement seeks out technologies and methodologies to reduce environmental impacts from current and past Navy operations, and applies to Navy installations worldwide. NEXWC is interested in environmental technologies and methodologies that are either new, innovative, advance the state-of-the art, or increase knowledge or understanding of a technology or methodology. https://sam.gov/opp/31a0cb3fe2fc4777b2f723ebe37a7d59/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 3/21/23
163.	C4ISR, Information Operations, Cyberspace Operations and Information Technology System Research, Cryogenics & Quantum (DoD/Navy) N66001-22-S-4703	Submissions in response to this announcement shall be for areas relating to the advancement of Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance (C4ISR) capabilities, enabling technologies for Information Operations and Cyberspace Operations, and Information Technology systems. https://sam.gov/opp/751823f9f7724854b4bc0c6b08c4c857/view	Dependent upon proposal	White papers accepted on a rolling basis until: 6/7/23

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		USAMRDC EXTRAMURAL BAA (1)		
164.	USAMRDC Broad Agency Announcement for Extramural Medical Research (DoD/USAMRDC) W81XWH18SBAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; Military Operational; Clinical and Rehabilitative Medicine; Medical Biological Defense; Medical Chemical Defense; Medical Simulation and Information Sciences Research Program. https://www.grants.gov/web/grants/view-opportunity.html?oppId=297726	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/22 Full proposal by invitation
		USSOCOM EXTRAMURAL R&D (1)		
165.	Dept. of the Army, USAMRAA – BAA for Extramural Biomedical Research and Development (DoD/USAMRAA) W81XWH-18-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries, prolonged field care, human performance optimization, and canine medicine/performance. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/web/grants/view-opportunity.html?oppId=307754	Dependent upon proposal	Proposals accepted through 7/31/23 Submission of a pre-proposal is required
		VISION HEALTH (8)		
166.	NEI Clinical Research Study Planning Grant Program (R34 Clinical Trial Not Allowed) (NIH/NEI) PAR-22-128	This grant is designed to (1) permit early peer review of the rationale for the proposed clinical trial or epidemiology study, (2) provide support for the development of a complete study protocol and associated documents, including a detailed MOP, (3) support the development of other essential elements of the clinical study. https://grants.nih.gov/grants/guide/pa-files/PAR-22-128.html	Up to $150,000 per year, for up to 2 years	Proposal: 6/16/22
167.	NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed) (NIH/NEI) PAR-22-135	This FOA provides support for activities central to the refinement and completion of a study protocol and procedures necessary for implementing a clinical trial to evaluate interventions that restore vision in humans through regeneration of cells in the eye and visual system. https://grants.nih.gov/grants/guide/pa-files/PAR-22-135.html	Up to $150,000 per year, for up to 2 years	Proposal: 6/16/22
168.	NEI Research Grant for Vision-Related Secondary Data Analysis (R21 Clinical Trial Not Allowed) (NIH/NEI) PAR-22-141	The purpose of this FOA is for secondary data analysis using existing data sets from vision-related clinical trials, epidemiologic, and other clinical research studies. This FOA may be used to develop new statistical methodologies or test hypotheses using existing data, but this FOA must not be used to support the collection of new data. https://grants.nih.gov/grants/guide/pa-files/PAR-22-141.html	Up to $275,000, for up to 2 years	Proposal: 6/16/22

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		VISION HEALTH		
169.	NEI Cooperative Agreement for Early-Stage Clinical Trials with Greater than Minimal Risk (U01 Clinical Trial Required) (NIH/NEI) PAR-22-149	This FOA invites U01 applications for early-stage clinical trials that are greater than minimal risk but are not administratively complex. Projects that are administratively complex often involve several recruiting clinical centers, an independent data coordinating center and often include resource centers. The proposed trials using this U01 mechanism typically are Phase I or II trials with strong scientific rationale and must evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders. https://grants.nih.gov/grants/guide/pa-files/PAR-22-149.html	Dependent upon proposal, for up to 5 years	Proposal: 9/23/22

170.	FY22 Vision
	Investigator- Initiated Research Award (IIRA)
	Clinical Trial Award (CTA)
	Focused Translational Team Science Award (FTTSA)
	Translational Research Award (TRA)
	(DoD/CDMRP)
	
	W81XWH-22-VRP-IIRA
	W81XWH-22-VRP-CTA
	W81XWH-22-VRP-FTTSA
	W81XWH-22-VRP-TRA
		Applications submitted to the FY22 VRP must address one or more of the following Focus Areas:
		• Eye injury or visual dysfunction as related to military exposure. Examples of military exposure may include, but are not limited to:
		  ○ Blast, penetrating, blunt, thermal, or chemical trauma
		  ○ Directed energy weapons such as laser, high-power microwaves, particle beams and ionizing radiation
		• Diagnosis, stabilization, and treatment of eye injuries in austere environments and prolonged field care settings
		• Restoration of visual function after military exposure-related vision loss or severe visual impairment.
		https://cdmrp.army.mil/funding/vrp
			Up to $4 million, for up to 4 years
			Dependent upon award mechanism
				Pre-application: 7/15/22
				Proposal: 11/9/22

		WARFIGHTER MEDICAL OPTIMIZATION DIVISION (1)		
171.	Airman Readiness Medical Research (ARMR) Hybrid BAA (DoD/Air Force) FA8650-20-S-6008	The Warfighter Medical Optimization Division intends to solicit White Papers under this announcement with the focus of conducting medical research in support of optimizing of the warfighter by enabling, enhancing, restoring, and sustaining the Airman to more effectively execute the Air Force mission. This medical research objective is dual natured: (1) ensure medical availability of Airmen by analyzing attributes (sensory, behavioral, physiologic) and operational environments (chemical, physical, psychological, biological, radiological stressors) to drive optimal performance of Airmen engaged in high-demand, high-impact mission tasks (2) investigate how the flight environment affects the process of life, the ability to maintain homeostasis, and the risk for injury or secondary insult, seeking to ameliorate these stressors to optimize Airman health and performance. https://www.grants.gov/web/grants/view-opportunity.html?oppId=327332	Up to $49 million, per award	White papers accepted on rolling basis until 4/30/26